Nilotinib (AMN-107) , ≥99% , 641571-10-0
CAS NO.:641571-10-0
Empirical Formula: C28H22F3N7O
Molecular Weight: 529.52
MDL number: MFCD09833716
EINECS: 700-544-5
Pack Size | Price | Stock | Quantity |
25MG | RMB63.20 | In Stock |
|
100MG | RMB119.20 | In Stock |
|
250MG | RMB216.80 | In Stock |
|
1g | RMB544.00 | In Stock |
|
5g | RMB2228.00 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 231-233 °C |
Density | 1.36 |
storage temp. | -20°C Freezer |
solubility | Soluble in DMSO (up to 50 mg/ml) |
form | Beige powder. |
color | Off-white |
Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
InChIKey | HHZIURLSWUIHRB-UHFFFAOYSA-N |
SMILES | N1(C=C(C)N=C1)C1C=C(C=C(C=1)NC(=O)C1C=CC(C)=C(NC2=NC=CC(C3=CC=CN=C3)=N2)C=1)C(F)(F)F |
CAS DataBase Reference | 641571-10-0(CAS DataBase Reference) |
Description and Uses
Chronic myeloid leukemia (CML), a hematological stem-cell disorder, is definitively diagnosed by the detection of the Philadelphia chromosome, a truncated version of chromosome 22 resulting from the reciprocal translocation of chromosomes 9 and 22 induced by a single mutagenic event. The consequence is the juxtaposition of two genes creating a fusion gene BCR-ABL. This gene leads to the translation of a fusion protein with increased tyrosine kinase activity that contributes to the pathogenesis of CML. Targeting the BCR-ABL protein has led to the successful intervention of the disease. Now established as first-line therapy for CML, imatinib was the first selective tyrosine kinase inhibitor of BCR-ABL. Since imatinib only binds to an inactive conformation of the ABL kinase portion, the conformational restrictions contribute to its selectivity.
Nilotinib, an orally active signal transduction inhibitor that selectively inhibits the tyrosine kinase Bcr-Abl, was discovered and developed by Norvartis and was launched for the treatment of chronic myeloid leukemia (CML) in patients with Philadelphia chromosome-positive (Ph+) disease who are resistant or intolerant to imatinib mesilate. Additional clinical trials are currently underway for the treatment of acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs).
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H315-H319-H335 |
Precautionary statements | P261-P305+P351+P338 |
HS Code | 29335990 |
Hazardous Substances Data | 641571-10-0(Hazardous Substances Data) |